Resource Center

Filter By

Resources
Google Acquiring Fitbit: The Battle for the Personal Health Record starts with a Skirmish for…

Google Acquiring Fitbit: The Battle for the Personal Health Record starts with a Skirmish for Consumer Wearables Google’s acquisition of FitBit has resulted in many great stories recounting the ins and outs of the fitness tracker and smartphone wars, Google’s troubled attempts to get a toehold in the wearables space,…

Read More
Resources
Patients With Persistently Low MELD-Na Scores Continue to be at Risk of Liver Related Death

Nikhilesh R. Mazumder, Kofi Atiemo, Amna Daud, Abel Kho, Michael Abecassis, Josh Levitsky, and Daniela P. Ladner
Most patients with cirrhosis have low Model for End-Stage Liver Disease-Sodium (MELD-Na) scores. The ability for the MELD-Na score to predict patient outcomes at low scores remains unclear. The researchers were able to link data from across Chicago to understand what patients might be eligible; from there, 7922 patients were identified, with 3999 patients having low MELD-Na scores. Further analyses were performed to show that, though patients with high MELD-Na scores had higher rates of mortality and were more likely to die of liver-related causes, even patients with low MELD-Na scores had high rates of liver-related mortality.

LEARN MORE
Resources
Introducing Datavant for Clinical Trials

We are excited today to announce Datavant for Clinical Trials, a solution that makes it easy for sponsors, CROs, and regulators to confidently bridge traditional clinical trial data with real-world data. This morning, we announced a multi-year strategic partnership with Parexel to roll out this connectivity solution across all of…

Read More
Resources
Advancing the Frontier of Privacy-Preserving Technology in Healthcare

Datavant’s mission is to connect the world’s health data, and make it accessible for valuable research and analytics. The traditional approach of aggregating data creates a direct tradeoff between individual privacy and analytical capability. With health data, this isn’t good enough. The stakes are high — data-driven decisions can save lives, just…

Read More
Resources
Guiding Philosophies for Recruiting World Class Teams in Tech

As the Head of People at a fast growing tech startup in San Francisco, I’ve had the pleasure to meet hundreds of candidates and refine the way we approach hiring and talent at Datavant. These are my guiding philosophies, which may help other teams who are developing their approach to…

Read More
Resources
Datavant’s Comments to CMS on Patient Matching

Datavant is a health data technology company focused on facilitating the exchange of patient information in a privacy-preserving way. Our software de-identifies patient health data and provides a secure method of linking patient records across disparate datasets without compromising individual privacy. Datavant’s de-identification and linking software is installed at over…

Read More
Learning about my genetic mutation (BRCA2), and optimism for the future of health research.
Learning about my genetic mutation (BRCA2), and optimism for the future of health research

Learning about my genetic mutation (BRCA2), and optimism for the future of health research Last month, I decided to try Color — one of several new personal genetic sequencing tools. Color screens for genetic mutations associated with various cancers and other diseases. As a health data geek, and as a patient with a…

Read More
Resources
Administrative Claims Data to Support Pragmatic Clinical Trial Outcome Ascertainment on Cardiovascular Health

Qinli Ma, Haechung Chung, Sonali Shambhu, Matthew Roe, Mark Cziraky, W. Schuyler Jones, and Kevin Haynes
This study examined a retrospective cohort as part of the ADAPTABLE trial (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness). The trial was designed to compare the efficacy of different doses of Aspirin for the prevention of atherosclerotic cardiovascular disease events. By linking claims data from Anthem with data from the Patient-Centered Outcomes Research Network (PCORnet), the investigators were able to follow participants and understand their health outcomes without direct follow-up or bringing them into a trial site.

LEARN MORE
Resources
The Hispanic Paradox in Patients With Liver Cirrhosis: Current Evidence from a Large Regional Retrospective Cohort Study

Kofi Atiemo, Nikhilesh R. Mazumder, Juan C. Caicedo, Daniel Ganger, Elisa Gordon, Samantha Montag, Haripriya Maddur, Lisa B. VanWagner, Satyender Goel, Abel Kho, Michael Abecassis, Lihui Zhao, and Daniela Ladner
Despite lower socioeconomic status, Hispanics in the United States have equal or higher survival rates compared to non-Hispanic whites (NHW). The authors attempted to understand whether this “Hispanic Paradox” applied to survival rates of liver cirrhosis. Using retrospective data from 20,121 patients in a Chicago-wide database linked together through Datavant technology, the researchers established that, controlling for age, sex, comorbidities, etiology of cirrhosis, and insurance status, Hispanics did indeed have higher survival rates than NHW.

LEARN MORE